Compare TRX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | MYGN |
|---|---|---|
| Founded | 1990 | 1991 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 470.0M | 481.6M |
| IPO Year | 2002 | 1996 |
| Metric | TRX | MYGN |
|---|---|---|
| Price | $1.36 | $4.68 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 8 |
| Target Price | $1.70 | ★ $7.64 |
| AVG Volume (30 Days) | ★ 4.5M | 1.8M |
| Earning Date | 04-13-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $771,400,000.00 |
| Revenue This Year | $73.52 | $7.19 |
| Revenue Next Year | $109.74 | $5.64 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 2.33 |
| 52 Week Low | $0.27 | $3.76 |
| 52 Week High | $2.80 | $9.48 |
| Indicator | TRX | MYGN |
|---|---|---|
| Relative Strength Index (RSI) | 39.40 | 44.59 |
| Support Level | $0.32 | $4.24 |
| Resistance Level | $1.95 | $5.69 |
| Average True Range (ATR) | 0.12 | 0.32 |
| MACD | -0.06 | 0.00 |
| Stochastic Oscillator | 15.54 | 32.04 |
TRX Gold Corp is engaged in the exploration, development, and production of mineral property interests in the United Republic of Tanzania, focused on development and mining operations, and on exploring and evaluating its mineral properties. The business of exploring and mining for minerals involves a high degree of risk, and the underlying value of the mineral properties depends on the existence and economic recovery of mineral resources and reserves, as well as the ability to raise long-term financing to continue development. The company is focused on the Buckreef Gold Project, which comprises five prospects: Buckreef, Bingwa, Tembo, Eastern Porphyry, and Buziba, and includes three main mineralized zones: Buckreef South, Buckreef Main, and Buckreef North.
Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.